Skip to main content

Want a detailed portfolio tracker?

OverviewPerformanceMetricsFinancialsETFsIndustryCorrelations
Market CapEPSP/EP/SP/BSharesProfit MarginOperating MarginDebt to EquityRevenueEarningsEBITDAFree Cash FlowTotal DebtTotal AssetsROAROE

Halozyme Therapeutics (HALO) Debt to Equity (2008 - 2026)

Halozyme Therapeutics (HALO) debt to equity from Dec 31, 2008 to Mar 31, 2026. The current Halozyme Therapeutics (HALO) debt to equity is 976.43%. You can export chart.

All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.

Debt to Equity

Debt to Equity

Annual Debt to Equity change of Halozyme Therapeutics (HALO)

YearDebt to EquityChange
20254389.74%
+960.61%
2024413.89%
-76.86%
20231788.87%
+101.68%
2022886.98%
+99.27%
2021445.12%
+69.26%
2020262.98%
-40.05%
2019438.69%
+763.96%
201850.78%
-47.71%
201797.11%
-114.56%
2016-666.93%
-675.52%
2015115.88%
-3.90%
2014120.58%
-148.43%
2013-248.97%
-510.14%
201260.70%
N/A
20110.00%
N/A
20100.00%
N/A
20090.00%
N/A
20080.00%
N/A

Comparison Halozyme Therapeutics (HALO) debt to equity with competitors

Halozyme Therapeutics (HALO) debt to equity is 976.43%.

TickerNameDebt to EquityUpside
DRUGBright Minds Biosciences Inc0.03%-100.00%
ARVNArvinas Inc0.13%-99.99%
GHRSGH Research PLC0.16%-99.98%
ATHEAlterity Therapeutics Ltd0.18%-99.98%
CGONCg Oncology Inc0.27%-99.97%
PHVSPharvaris NV0.31%-99.97%
OSRHBellevue Life Sciences Acquisition Corp0.37%-99.96%
GLPGGalapagos NV0.37%-99.96%
VTVTvTv Therapeutics Inc - Class A0.46%-99.95%
BDRXBiodexa Pharmaceuticals Plc0.53%-99.95%
LPTXLeap Therapeutics Inc0.68%-99.93%
CMNDClearmind Medicine Inc0.74%-99.92%
CBUSCibus Global Ltd. Class A0.75%-99.92%
ABVCABVC BioPharma Inc0.82%-99.92%
COEPCoeptis Therapeutics Holdings Inc. Common Stock0.87%-99.91%
PPCBPropanc Biopharma Inc1.05%-99.89%
ARGXArgen X SE1.14%-99.88%
OCSOculis Holding AG1.14%-99.88%
XRTXXORTX Therapeutics Inc1.17%-99.88%
IMMPImmutep Ltd1.22%-99.87%
CANFCan-Fite Biopharma Ltd1.27%-99.87%
RVPHReviva Pharmaceuticals Holdings Inc1.33%-99.86%
BNTXBioNTech SE1.62%-99.83%
NBPNovaBridge Biosciences.1.74%-99.82%
NRXSNeuraxis Inc1.75%-99.82%
IMABI-Mab1.77%-99.82%
IFRXInflaRx N.V.2.23%-99.77%
ONCOOnconetix Inc2.47%-99.75%
ENTOEntero Therapeutics, Inc. Common Stock2.51%-99.74%
GANXGain Therapeutics Inc2.67%-99.73%
NCNANuCana plc3.04%-99.69%
ADXNAddex Therapeutics Ltd3.11%-99.68%
SXTP60 Degrees Pharmaceuticals Inc3.29%-99.66%
IMTXImmatics N.V3.31%-99.66%
YMABY-Mabs Therapeutics Inc3.66%-99.63%
IRONDisc Medicine Inc4.27%-99.56%
LGVNLongeveron Inc - Class A4.67%-99.52%
MOLNMolecular Partners AG4.89%-99.50%
NCELNLS Pharmaceutics Ltd4.90%-99.50%
ADAGAdagene Inc5.23%-99.46%
PRTCPureTech Health plc American Depositary Shares5.56%-99.43%
ALXOAlx Oncology Holdings Inc5.62%-99.42%
REGNRegeneron Pharmaceuticals Inc6.32%-99.35%
ANROAlto Neuroscience Inc6.58%-99.33%
MDXGMimedx Group Inc7.24%-99.26%
GDTCCytoMed Therapeutics Ltd7.37%-99.24%
MRNAModerna Inc7.96%-99.18%
QLGNQualigen Therapeutics, Inc. Common Stock8.40%-99.14%
BEAMBeam Therapeutics Inc8.60%-99.12%
PBYIPuma Biotechnology Inc8.79%-99.10%
PYPDPolypid Ltd9.00%-99.08%
KURAKura Oncology Inc9.04%-99.07%
SLNOSoleno Therapeutics Inc10.06%-98.97%
VRAXVirax Biolabs Group Ltd - Class A10.13%-98.96%
SVASinovac Biotech Ltd11.15%-98.86%
RIGLRigel Pharmaceuticals11.25%-98.85%
MAZEMaze Therapeutics Inc11.36%-98.84%
ABEOAbeona Therapeutics Inc12.48%-98.72%
CLDICalidi Biotherapeutics Inc12.62%-98.71%
ACIUAC Immune SA13.65%-98.60%
MNMDMind Medicine (MindMed) Inc. Common Shares14.62%-98.50%
VERAVera Therapeutics Inc - Class A15.01%-98.46%
ALTAltimmune Inc15.25%-98.44%
NUVBNuvation Bio Inc - Class A16.62%-98.30%
SVRASavara Inc17.08%-98.25%
ACHVAchieve Life Sciences Inc17.21%-98.24%
DYNDyne Therapeutics Inc17.27%-98.23%
HRMYHarmony Biosciences Holdings Inc17.45%-98.21%
SPRBSpruce Biosciences Inc18.66%-98.09%
RCUSArcus Biosciences Inc19.08%-98.05%
INVAInnoviva Inc19.24%-98.03%
MDWDMediWound Ltd19.62%-97.99%
TARSTarsus Pharmaceuticals Inc20.80%-97.87%
XNCRXencor Inc21.05%-97.84%
TCRXTscan Therapeutics Inc22.51%-97.70%
APLSApellis Pharmaceuticals Inc22.59%-97.69%
CNTACentessa Pharmaceuticals plc22.66%-97.68%
BMRNBiomarin Pharmaceutical Inc23.02%-97.64%
TSHATaysha Gene Therapies Inc23.10%-97.63%
FBIOFortress Biotech Inc23.12%-97.63%
MESOMesoblast Ltd23.52%-97.59%
HYFTMindWalk Holdings Corp23.71%-97.57%
ONCBeiGene Ltd24.13%-97.53%
LXRXLexicon Pharmaceuticals Inc24.49%-97.49%
NKTRNektar Therapeutics24.89%-97.45%
ICCCImmucell Corp29.87%-96.94%
CRSPCRISPR Therapeutics AG32.27%-96.70%
ZLABZai Lab Ltd32.30%-96.69%
QUREuniQure N.V.33.44%-96.58%
ABOSAcumen Pharmaceuticals Inc35.49%-96.37%
ALDXAldeyra Therapeutics Inc36.29%-96.28%
PRQRProQR Therapeutics N.V36.40%-96.27%
OBIOOrchestra BioMed Holdings Inc36.41%-96.27%
COGTCogent Biosciences Inc36.72%-96.24%
ELABPMGC Holdings Inc37.62%-96.15%
ASBPAspire Biopharma Holdings Inc38.75%-96.03%
MLTXMoonLake Immunotherapeutics - Class A38.98%-96.01%
LEGNLegend Biotech Corp40.23%-95.88%
PHXMPHAXIAM Therapeutics SA ADR42.62%-95.63%
PHARPharming Group N.V.43.21%-95.58%
XFORX4 Pharmaceuticals Inc44.52%-95.44%
REPLReplimune Group Inc50.14%-94.87%
ADMAAdma Biologics Inc50.44%-94.83%
CLGNCollPlant Biotechnologies Ltd New54.22%-94.45%
BLRXBioline Rx Ltd54.40%-94.43%
SRPTSarepta Therapeutics Inc55.69%-94.30%
ARQTArcutis Biotherapeutics Inc57.70%-94.09%
MDGLMadrigal Pharmaceuticals Inc62.62%-93.59%
CAICaris Life Sciences Inc - Class A64.29%-93.42%
SRRKScholar Rock Holding Corp71.23%-92.70%
INSMInsmed Inc76.93%-92.12%
ATAIATAI Life Sciences N.V.83.95%-91.40%
VRNAVerona Pharma Plc87.12%-91.08%
IONSIonis Pharmaceuticals Inc88.01%-90.99%
RYTMRhythm Pharmaceuticals Inc88.25%-90.96%
RPRXRoyalty Pharma plc - Class A90.13%-90.77%
CDXSCodexis Inc93.64%-90.41%
ALECAlector Inc94.08%-90.37%
GMABGenmab94.17%-90.36%
TTRXTurn Therapeutics Inc97.04%-90.06%
GERNGeron Corp109.92%-88.74%
XOMAXOMA Royalty Corp110.48%-88.68%
TLXTelix Pharmaceuticals Ltd112.45%-88.48%
HCWBHCW Biologics Inc114.14%-88.31%
JAZZJazz Pharmaceuticals plc118.15%-87.90%
MRVIMaravai LifeSciences Holdings Inc - Class A119.30%-87.78%
TGTXTG Therapeutics Inc127.78%-86.91%
ARDXArdelyx Inc136.94%-85.98%
FOLDAmicus Therapeutics Inc143.18%-85.34%
QNTMFSD Pharma Inc - Class B - Class B (Sub Voting)146.17%-85.03%
AAPGAscentage Pharma Group International149.47%-84.69%
SLXNSilexion Therapeutics Corp149.83%-84.66%
OPTOpthea Ltd156.18%-84.01%
SPRYARS Pharmaceuticals Inc157.44%-83.88%
NMRANeumora Therapeutics Inc159.82%-83.63%
MISTMilestone Pharmaceuticals Inc161.42%-83.47%
CLLSCellectis181.25%-81.44%
ASNDAscendis Pharma A/S183.75%-81.18%
FTREFortrea Holdings Inc200.32%-79.48%
AIMAIM ImmunoTech Inc.215.25%-77.96%
CELCCelcuity Inc257.58%-73.62%
HOWLWerewolf Therapeutics Inc262.95%-73.07%
VALNValneva SE273.15%-72.03%
ALLRAllarity Therapeutics Inc290.17%-70.28%
HUMAHumacyte Inc308.59%-68.40%
AXSMAxsome Therapeutics Inc344.13%-64.76%
ADAPAdaptimmune Therapeutics plc American Depositary Shares423.98%-56.58%
PGENPrecigen Inc462.16%-52.67%
OCGNOcugen Inc502.91%-48.50%
SNDXSyndax Pharmaceuticals Inc840.90%-13.88%
EDITEditas Medicine Inc1240.40%+27.03%
RVNCRevance Therapeutics Inc1477.84%+51.35%
IOBTIO Biotech Inc1829.20%+87.33%